Get the Stockscreener App
21.05
1.36%
-0.29
After Hours:
20.63
-0.42
-2.00%
Zenas Biopharma Inc stock is traded at $21.05, with a volume of 631.11K.
It is down -1.36% in the last 24 hours and down -12.44% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
See More
Previous Close:
$21.34
Open:
$21.44
24h Volume:
631.11K
Relative Volume:
0.76
Market Cap:
$1.31B
Revenue:
$10.00M
Net Income/Loss:
$-377.74M
P/E Ratio:
-2.493
EPS:
-8.4436
Net Cash Flow:
$-172.35M
1W Performance:
+0.91%
1M Performance:
-12.44%
6M Performance:
-22.01%
1Y Performance:
+141.40%
1-Day Range:
$20.50
$21.65
1-Week Range:
$20.13
$21.77
52-Week Range:
$8.09
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
21.05 | 1.33B | 10.00M | -377.74M | -172.35M | -8.4436 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
ZBIO Options Volatility — NASDAQ:ZBIO - TradingView — Track All Markets
ZBIO Options Chain — NASDAQ:ZBIO - TradingView — Track All Markets
Breakout Zone: Will Zenas BioPharma Inc outperform during market ralliesWeekly Investment Recap & Consistent Growth Stock Picks - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Big Picture: Is Zenas BioPharma Inc attractive at current valuationTake Profit & Safe Capital Growth Stock Tips - baoquankhu1.vn
Returns Recap: Can Zenas BioPharma Inc be the next market leader2026 Macro Impact & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Trend Review: What is the target price for Zenas BioPharma Inc stock2026 Fed Impact & AI Enhanced Trading Signals - baoquankhu1.vn
Investor Mood: What are Zenas BioPharma Incs growth levers2026 EndofYear Setup & Expert Approved Trade Ideas - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Experienced Healthcare Investor Buys Shares Of Zenas Biopharma – Insider Weekends (NASDAQ:ZBIO) - Seeking Alpha
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Assessing Zenas BioPharma (ZBIO) Valuation After US$300 Million Equity And Convertible Notes Financing - Sahm
Zenas BioPharma (ZBIO) Price Target Increased by 21.59% to 40.22 - MSN
Zenas BioPharma's Key Milestones and Market Context: Holding Through the BLA (NASDAQ:ZBIO) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
Zenas BioPharma Director Makes Bold New Move With Fresh Stock Purchase - TipRanks
Zenas BioPharma Director Increases Stake with $70K Stock Purchase - National Today
Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $70,197 By Investing.com - Investing.com Canada
Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $70,197 - Investing.com
Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) Director Buys 3,768 Shares of Stock - marketbeat.com
Leon Moulder boosts Zenas BioPharma (ZBIO) stake to 4.794% ownership - Stock Titan
Zenas BioPharma (ZBIO) director-affiliated funds purchase 3,768 shares - Stock Titan
Zenas BioPharma (NASDAQ:ZBIO) Trading Up 7.6% Following Insider Buying Activity - MarketBeat
2026-04-02 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect | NDAQ:ZBIO | Press Release - Stockhouse
Zenas BioPharma (NASDAQ:ZBIO) Director Purchases $3,000,000.00 in Stock - MarketBeat
Akin, an Elite Global Law Firm - Akin
Zenas BioPharma (ZBIO): Does This $300 Million Raise Clarify or Complicate Its Funding Strategy? - Sahm
Major Insider Move Signals Growing Confidence in Zenas BioPharma’s Future - TipRanks
Zenas Biopharma, Daqo New Energy and other big stocks moving lower in Friday's pre-market session - MSN
Fairmount fund adds 150,000 Zenas BioPharma (ZBIO) shares - Stock Titan
ZBIO6353884 Bond Price and Chart — FINRA:ZBIO6353884 - TradingView
Zenas BioPharma, Inc. Bonds — Corporate Bond Rates - TradingView — Track All Markets
Zenas BioPharma Insider Bought Shares Worth $1,021,140, According to a Recent SEC Filing - marketscreener.com
Insider Makes Bold Million-Dollar Bet on Zenas BioPharma - TipRanks
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ZBIO Stock Price and Chart — NASDAQ:ZBIO - TradingView
54K-share open-market buy by CEO-linked entities at Zenas BioPharma (ZBIO) - Stock Titan
Zenas BioPharma Raises Capital via Notes and Equity Offering - TipRanks
Zenas BioPharma (ZBIO) CEO Moulder buys shares worth $1.02 million By Investing.com - Investing.com Australia
Zenas BioPharma (ZBIO) CEO Moulder buys shares worth $1.02 million - investing.com
Lu Hongbo buys $1.5 million in Zenas Biopharma (ZBIO) stock - Investing.com
Lu Hongbo buys $1.5 million in Zenas Biopharma (ZBIO) stock By Investing.com - Investing.com Canada
Director-linked funds add 75K Zenas BioPharma (ZBIO) shares at $20 in offering - Stock Titan
Zenas BioPharma (ZBIO) raises capital via $200M converts and equity sale - Stock Titan
Form 424B5 Zenas BioPharma, Inc. - StreetInsider
Zenas BioPharma (NASDAQ: ZBIO) prices $200M convertible notes due 2032 - Stock Titan
[424B5] Zenas BioPharma, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock Upside - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma announces concurrent public offerings of convertible senior notes and common stock - MSN
Zenas Biopharma Inc Stock (ZBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):